Amtagvi revenue crosses $100 million as margin hits 60%
- Amtagvi is the core growth driver, crossing $100 million in Q3 2026 revenue.
- Gross margin reached a record 60% in Q3 2026 due to internal manufacturing scale.
- Iovance expects its cash runway to fund operations well into 2029.
- The company anticipates UK and Swissmedic regulatory decisions by early 2027.
- The pipeline could add larger cancer markets, with a targeted U.S. NSCLC submission in 2027.
A real launch gaining speed
Iovance is moving past its early launch growing pains. Amtagvi demand is strong, with management reporting over $100 million in Q3 2026 Amtagvi revenue. That number proved the market needs the product and pushed total revenue to $122 million. The company is now verging on profitability, with earnings per share losses narrowing to just $0.05.
The bull case is that Iovance owns a first mover position in tumor infiltrating lymphocyte therapy, often called TIL therapy. In plain English, doctors take immune cells from a patient's tumor, grow them outside the body, then put them back to attack the cancer. The gross margin reaching 60% in Q3 2026 shows the internal factory can run efficiently as volume grows.
The bear case is that this is still hard medicine to make and sell, and international expansion is taking time. Ex-U.S. approvals in the UK and Europe are pending, and setting up international reimbursement is a slow process.
The next proof points are clear: securing UK and Swissmedic approvals in early 2027, finalizing the NSCLC trial dataset for a 2027 submission, and progressing the new POSITILITY biomarker cohort.
A custom therapy factory
Iovance makes money from Amtagvi, its FDA-approved personalized TIL therapy for advanced melanoma, and Proleukin, an IL-2 drug used with the treatment. Each Amtagvi treatment is made from a specific patient's tumor cells, making this closer to a custom factory than a normal drug plant.
The company says its moat is the 22-day Gen 2 manufacturing process and the internal Iovance Cell Therapy Center in Philadelphia, also called iCTC. Centralizing production there helped gross margin reach 60% in Q3 2026. The facility will also handle international commercial launches without the need for overseas plants.
Proleukin is tied to Amtagvi use. Iovance expects treatment centers to use about 15 Proleukin vials per Amtagvi infusion, and Proleukin sales can lead Amtagvi infusions by 2 to 3 months. That makes Proleukin a useful demand signal, not just a separate product.
To reach more patients, Iovance is adding specialty pharmacy distribution, including McKesson Biologics. The network has grown to over 100 active treatment centers, with community hospitals making up over a third of the total.
Amtagvi plus bigger bets
Amtagvi
Amtagvi, also called lifileucel, is the main product and is FDA-approved for advanced melanoma. It is also approved in Australia and Canada.
Proleukin
Proleukin, or aldesleukin, is used as part of the Amtagvi treatment regimen. Iovance expects about 15 vials per Amtagvi infusion.
NSCLC lifileucel program
Iovance is studying lifileucel in previously treated non-small cell lung cancer. The program targets a 2027 submission and includes a biomarker cohort showing a 59.1% response rate.
Sarcoma lifileucel program
A registrational trial is underway in advanced sarcomas. The company aligned with the FDA on a potential accelerated pathway targeting a 2028 or 2029 submission.
Endometrial cancer program
Iovance reported a 40% confirmed objective response rate for lifileucel in metastatic serous endometrial cancer. More data are needed before this becomes a commercial product.
IOV-5001 and IOV-3001
IOV-5001 is an IL-12-tethered TIL therapy with a clinical trial underway. IOV-3001 is a next-generation IL-2 candidate meant to improve dosing.
One segment, two revenue lines
Iovance reports as one operating segment. The mix below uses Q3 2026 results: Amtagvi revenue of over $100 million inside total revenue of $122 million.
What could go wrong
Manufacturing does not scale cleanly
High impact · Medium oddsAmtagvi is made from each patient's own tumor cells. That makes quality, timing, and raw materials harder to control than a normal drug. Gross margin hit 60% in Q3 2026, but the company must maintain that efficiency as volume grows.
Pipeline data fail to expand the market
High impact · Medium oddsThe long-term upside depends on moving TIL therapy beyond melanoma. NSCLC, sarcoma, and endometrial cancer could make the market much bigger. Weak response data or slow enrollment would leave Iovance dependent on melanoma.
Ex-U.S. approvals take longer
Medium impact · Medium oddsAustralia and Canada approved Amtagvi, but Europe and the UK remain pending. Iovance resubmitted its UK application in July 2026 and expects a decision in early 2027. Delays push back international revenue.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Iovance Biotherapeutics, Inc. in Finn's Biotechnology industry ranking.

